Clinical studies on the radioimmunodetection of tumors containing alpha-fetoprotein

Goldenberg, David M.; Edmund, E.; DeLand, Frank H.; Spremulli, Ellen N.; Nelson, Melissa; Gockerman, Jon P.; Primus, F. James; Corgan, Robert L.; Alpert, Elliot

doi:10.1002/1097-0142(19800515)45:10<2500::aid-cncr2820451006>3.0.co;2-j

Cited by 114 publications

(18 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, it is desirable to achieve a high gradient between the boron-10 concentration in tumor as compared to adjacent normal tissues. Recent clinical studies have affirmed that a number of antitumor antibodies can accrete selectively in tumors containing the appropriate antigen target, and when these antibodies are labeled with a suitable radionuclide, tumor imaging (radioimmunodetection of cancer) is achieved (3)(4)(5)(6)(7)(8)(9). Thus, it became apparent to us that the conditions were ripe for a reexamination of the potential use of antitumor antibodies as a vehicle for bringing boron-10 into tumors as neutron-capture agents.…”

mentioning

confidence: 99%

Neutron-capture therapy of human cancer: in vivo results on tumor localization of boron-10-labeled antibodies to carcinoembryonic antigen in the GW-39 tumor model system.

Goldenberg¹,

Rm²,

Primus³

et al. 1984

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Neutron-capture therapy of human cancer: in vivo results on tumor localization of boron-10-labeled antibodies to carcinoembryonic antigen in the GW-39 tumor model system.

Goldenberg¹,

Rm²,

Primus³

et al. 1984

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…200/ 165/145 (three successive studies) had a previous positive afetoprotein radioscan, the hCG RaID study was unrevealing, consistent with the patient's normal serum hCG level. Likewise, normal goat IgG given to this patient did not reveal the lung metastases seen in the chest roentgenogram (9). In terms of the method's specificity in this series, 21 sites known to be free of tumor (as determined by other detection methods) were all negative by hCG RaID.…”

Section: Resultsmentioning

confidence: 57%

“…In cancer, the use of antibodies directed against qualitatively distinct or quantitatively increased substances (tumor "markers") contained in neoplasms permits the visualization oftumor sites by this technology (1,2) and has been applied clinically to detect tumors bearing carcinoembryonic antigen (CEA), a-fetoprotein, and human chorionic gonadotropin (hCG) (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14).…”

mentioning

confidence: 99%

Human chorionic gonadotropin radioantibodies in the radioimmunodetection of cancer and for disclosure of occult metastases.

Goldenberg¹,

Kim²,

DeLand³

1981

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Radioimmunodetection (RaID) of tumors containing human chorionic gonadotropin (hCG; choriogonadotropin) was evaluated in 25 patients by injecting "3'I-labeled goat antibody IgG against hCG and performing total-body photoscans with a y scintillation camera 24 and 48 hr later. All 10 testicular cancer patients with proven tumor sites had positive RaID results, whereas three cases without known tumor were negative. Four patients with hydatidiform mole and one with degenerative products of conception showed positive RaID results consistent with elevated serum hCG titers. Two putatively false-positive results were obtained in patients with lung or ovarian cancer, whereas a false-negative metastasis to the liver ofa patient with lung cancer and an elevated serum hCG titer was observed. Of 14 tumor sites found by RaID in 10 testicular cancer patients, 4 were revealed by RaID prior to any other detection method used and provided a lead time to definitive diagnosis by other measures of a few days to >1 yr. Although arnumber ofpatients had high serum hCG levels, even exceeding 3 ,ug/ml, the xenogeneic antibody was capable oflocalizing in tumor. No adverse effects were noted in any of the patients studied. Thus, hCG RaID appears to be a safe and effective method of detecting and locating hCG-producing tumors and has been found to disclose occult testicular cancers.Radioimmunodetection (RaID) is the method by which antibodies are used to transport diagnostic amounts ofradioactivity to specific sites of the body for the external scintigraphic demonstration of abnormal sequestration of radioactivity in pathological tissues. In cancer, the use of antibodies directed against qualitatively distinct or quantitatively increased substances (tumor "markers") contained in neoplasms permits the visualization oftumor sites by this technology (1, 2) and has been applied clinically to detect tumors bearing carcinoembryonic antigen (CEA), a-fetoprotein, and human chorionic gonadotropin (hCG) (3-14).The application of RaID appears to be particularly indicated in patients in whom a tumor marker is shown to be increased in the blood, and where the sites of tumor or of marker production are suspected or unknown. We now communicate our experience with RaID using hCG antibodies, emphasizing the use of this approach to disclose occult metastases of testicular cancer.MATERIALS AND METHODS Subjects. RaID was applied to 25 consecutive patients with putative hCG-producing lesions. Thirteen had a history of histologically confirmed testicular cancer and were evaluated for the presence of primary, recurrent, or metastatic disease. In addition, five patients with hCG-secreting hydatidiform moles or uterine choriocarcinoma, patients with diverse ovarian and lung tumors, and a case with degenerative products of conception were included. Tumor sites were confirmed by surgery, biopsy, ultrasonography, radiological studies including computed tomography (CT), arteriography, venacavography, intravenous pyelography, and by other firm clinical evidence...

show abstract

“…A variety of radiolabeled antibodies (whole IgG) specific for tumor-associated antigens have been used to image cancers by external photoscanning techniques (radioimmunodetection) using antibodies specific for carcinoembryonic antigen (18), alpha-fetoprotein (19), human chorionic gonadotropin (20), a kidney carcinoma antigen (21), and ferritin (22). Initial reports cited a diagnostic accuracy of 85% (17,18).…”

Section: Resultsmentioning

confidence: 99%

Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy.

Larson¹,

Carrasquillo²,

Krohn³

et al. 1983

J. Clin. Invest.

237

View full text Add to dashboard Cite

A B S T R A C T 33 patients with advanced malignant melanoma were studied after intravenous administration of "3'I-labeled Fab fragments specific for p97, an oncofetal glycoprotein of human melanoma. In all, 47 gamma camera imaging studies were performed for the purpose of localization of metastatic deposits. In addition to tumor, 131I-Fab uptake was also seen in liver and kidney. 20 of these studies included simultaneous administration of both an 31I-labeled Fab specific for p97, and an '25I-labeled Fab not specific for p97. Blood clearance of p97-specific Fab was significantly more rapid than for nonspecific Fab. Eight of these patients had biopsies of subcutaneous nodules at 48 and 72 h postinjection in order to assess whether localization of radioactivity was antigen specific. Antigen-specific localization was observed with average ratios of specific/ nonspecific uptake of 3.7 (48 h) and 3.4 (72 h); uptake was strongly correlated with tumor p97 concentration (r = 0.81, P < 0.01). Also, imaging studies of the biodistribution of 131I-labeled anti-p97 Fab in patients selected for high p97 tumor concentration showed avid tumor uptake and more prolonged retention of labeled Fab in tumor than in normal tissues.Based on these studies, we estimated that total '31I doses of 500 mCi could be safely given to patients

show abstract

Clinical studies on the radioimmunodetection of tumors containing alpha-fetoprotein

Cited by 114 publications

References 11 publications

Neutron-capture therapy of human cancer: in vivo results on tumor localization of boron-10-labeled antibodies to carcinoembryonic antigen in the GW-39 tumor model system.

Neutron-capture therapy of human cancer: in vivo results on tumor localization of boron-10-labeled antibodies to carcinoembryonic antigen in the GW-39 tumor model system.

Human chorionic gonadotropin radioantibodies in the radioimmunodetection of cancer and for disclosure of occult metastases.

Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy.

Contact Info

Product

Resources

About